ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2899

Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway

Xavier M Teitsma1, Johannes W. G. Jacobs2, Arno N Concepcion3, Attila Pethö-Schramm4, Michelle EA Borm5, Jacob van Laar1, Johannes W. J. Bijlsma6 and Floris PJG Lafeber1, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, 2Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4F. Hoffmann-La Roche, Basel, Switzerland, 5Roche Nederland BV, Woerden, Netherlands, 6Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biomarkers, methotrexate (MTX), proteomics, rheumatoid arthritis (RA) and transcriptional regulation

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Wednesday, October 24, 2018

Session Title: 6W009 ACR Abstract: RA–Etiology & Pathogenesis II (2898–2903)

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: We previously identified several co-expressed genes associated with achieving sustained drug-free remission (sDFR) following a methotrexate (MTX)-based strategy in early rheumatoid arthritis (RA).1 The aim of the present analyses was to identify, within the same patients, inflammatory proteins associated with achieving sDFR and to study associated biological pathways and compare these with those previously found in the transcriptomic analyses.

 

Methods: Data was used from patients participating in the U-Act-Early trial who achieved sDFR (i.e. being drug-free for ≥3 months) after therapy with a treat-to-target MTX-based strategy (n=10).2 When the treatment target, sustained remission (disease activity scores assessing 28 joints (DAS28) <2.6 and ≤4 swollen joints for ≥24 weeks), was achieved, therapy was tapered and thereafter discontinued. Controls were patients without a drug-free period during the study (n=7). In baseline serum samples, 85 proteins were measured and analysed using multi-analyte profiling. Partial least square discriminant analysis (PLSDA) was used to identify relevant proteins, which were subsequently used for pathway analyses in the Genes Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases.

Results: Table 1 shows baseline clinical characteristics; no significant differences were found between those achieving sDFR vs. controls (p>0.14). PLSDA identified 13 proteins, of which pathway analyses yielded 117 significant GO terms and 14 KEGG pathways (Fig. 1). Comparison of the significantly enriched pathways found in the transcriptomic analyses and those in the present study yielded 33 corresponding GO terms, including “janus kinase signal transducer and activator of transcription (JAK-STAT) cascade” (p≤8.97E-03) and “positive regulation of tyrosine phosphorylation of STAT protein” (p≤8.37E-03), which is important for signal transduction in the JAK-STAT pathway. Additionally, one KEGG pathway (“JAK-STAT signalling pathway”) was also found to be significantly enriched in both transcriptional and proteomic analyses (p≤2.22E-04).

Conclusion: Biological processes important for effectively reducing inflammation in new-onset RA, treated to target with a MTX-based strategy, were found to be associated with activity of JAK-STAT signalling components. Involvement of this pathway was found both in the analyses of the transcriptome and proteome, demonstrating a specific JAK-STAT profile at baseline affects the immunosuppressive efficacy of MTX.

References:

1. Teitsma XM, et al. Arthritis Res Ther 2017;19:170.

2. Bijlsma JW, et al. Lancet 2016;388:343-55.

 


Disclosure: X. M. Teitsma, None; J. W. G. Jacobs, None; A. N. Concepcion, None; A. Pethö-Schramm, F Hoffmann-La Roche, 3; M. E. Borm, Roche Nederland BV, 3; J. van Laar, Arthrogen, MSD, Pfizer, Eli Lelly, BMS, Astra Zeneca, Roche-Genentech, 2, 5; J. W. J. Bijlsma, Roche, AbbVie, Bristol-Myers, Squibb, Merck Sharp and Dohme, Pfizer, UCB, 2, 5; F. P. Lafeber, None.

To cite this abstract in AMA style:

Teitsma XM, Jacobs JWG, Concepcion AN, Pethö-Schramm A, Borm ME, van Laar J, Bijlsma JWJ, Lafeber FP. Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/sustained-drug-free-remission-in-early-ra-following-methotrexate-based-strategy-role-of-the-jak-stat-pathway/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-drug-free-remission-in-early-ra-following-methotrexate-based-strategy-role-of-the-jak-stat-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.